Dr. Michael W. Roppolo, MD
Nephrology (Kidney) (Nephrology Physician)
5131 Odonovan Dr Ste 100
Baton Rouge, LA 70808
Who else practices at this address →
East Baton Rouge Parish includes primary care (46% of residents) shortage areas. About shortage areas
- Medicare participating
At a glance
- Medical school
- University of Arkansas College of Medicine (1993)
- Years since graduation
- 33
- In the NPI registry since
- 2005
- Medicare patients seen, 2024
- 498
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1993Medical school: University of Arkansas College of Medicine
- 2005Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Nephrology Physician primary
LA license 020172
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Our Lady of the Lake Regional Medical Center Baton Rouge, LA
- Ochsner Medical Center - Baton Rouge Baton Rouge, LA
- Baton Rouge General Medical Center Baton Rouge, LA
Medical groups
- Ochsner Clinic LLC (2,864 clinicians)
- Renal Associates of Baton Rouge, LLC (26 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 498
- Services billed
- 2,565
- Patients’ average age
- 70
| Service | Times | Patients |
|---|---|---|
| Injection, darbepoetin alfa, 1 microgram (non-esrd use) | 3,990 | 33 |
| Home dialysis services per month (20 years or older) | 379 | 78 |
| Established patient office or other outpatient visit, 30-39 minutes | 313 | 201 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 303 | 151 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 62 | 36 |
| Injection of drug or substance under skin or into muscle | 52 | 32 |
| Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | 36 | 33 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 27 | 26 |
| New patient office or other outpatient visit, 45-59 minutes | 14 | 14 |
| Office or other outpatient visit for the evaluation and management of established patient that may not require presence of healthcare professional | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Losartan Potassium Other prescribers in Baton Rouge, LA | 156 |
| Furosemide Other prescribers in Baton Rouge, LA | 123 |
| Amlodipine Besylate Other prescribers in Baton Rouge, LA | 118 |
| Farxiga (dapagliflozin propanediol) Other prescribers in Baton Rouge, LA | 113 |
| Jardiance (empagliflozin) Other prescribers in Baton Rouge, LA | 95 |
| Carvedilol Other prescribers in Baton Rouge, LA | 90 |
| Hydralazine Hcl Other prescribers in Baton Rouge, LA | 77 |
| Lisinopril Other prescribers in Baton Rouge, LA | 69 |
| Spironolactone Other prescribers in Baton Rouge, LA | 67 |
| Doxazosin Mesylate Other prescribers in Baton Rouge, LA | 58 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 14 companies reported 49 payments worth $5,065 in total to this clinician.
| Fresenius USA Marketing, Inc. | $4,367 |
|---|---|
| Novartis Pharmaceuticals Corporation | $158 |
| Vifor Pharma, Inc. | $145 |
| Otsuka America Pharmaceutical, Inc. | $75.96 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $53.75 |
| Akebia Therapeutics Inc | $51.88 |
| Alexion Pharmaceuticals, Inc. | $46.05 |
| AstraZeneca Pharmaceuticals LP | $34.32 |
| Consulting Fee | $2,400 |
|---|---|
| Food and Beverage | $1,574 |
| Travel and Lodging | $1,070 |
| Education | $21.00 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Fresenius USA Marketing, Inc. Aug 27, 2025 | Consulting Fee | $2,400 |
| Fresenius USA Marketing, Inc. Aug 27, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $721 |
| Fresenius USA Marketing, Inc. Aug 27, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $313 |
| Fresenius USA Marketing, Inc. Aug 27, 2025 | Travel and Lodging travel to Boston, MA · in-kind | $35.01 |
| Fresenius USA Marketing, Inc. Aug 27, 2025 | Education in-kind | $21.00 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $237,728 in research payments for these studies, mostly to the institutions running them.
- Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)
Csl Behring · Recruiting · NCT05485961
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.